Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C – data from an Austrian “real-life”-cohort

The combination of the two pangenotypic direct-acting antivirals glecaprevir and pibrentasvir has recently been approved for treatment of all HCV genotypes. In phase-2 and phase-3 trials sustained virological response rates (SVR) exceeding 95% have been reported with this regimen. However, only limited “real-life”-data with glecaprevir/pibrentasvir have been presented so far.